The MYG1 Knockout HeLa Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the MYG1 gene in the HeLa host background. This loss-of-function model enables systematic investigation of MYG1-dependent molecular mechanisms without clonal selection artifacts, providing a heterogeneous knockout pool suitable for population-level phenotypic and biochemical analyses. The polyclonal format facilitates robust experimental replication by reflecting the stochastic nature of CRISPR/Cas9-mediated gene disruption across a cell population, avoiding biases associated with single-cell-derived clones and ensuring broad applicability in functional genomic studies.
HeLa cells are an extensively characterized human cervical adenocarcinoma epithelial line originally derived from an HPV-18 positive cervical carcinoma. Their robust proliferative capacity, well-documented karyotype, and susceptibility to a wide range of genetic manipulation methods make them a workhorse model in cancer biology and molecular cell biology. The HPV-18 oncoproteins E6 and E7 interfere with TP53 and RB tumor suppressor pathways, establishing a pro-survival context that synergizes with mitochondrial regulatory perturbations, thereby offering a highly relevant backdrop for dissecting the contributions of mitochondrial proteins such as MYG1 to tumor cell physiology.
MYG1 encodes a mitochondrial protein that localizes to the organelle via interaction with the mitochondrial import receptor TOMM20 and associates with prohibitin complexes, contributing to the maintenance of mitochondrial membrane integrity and oxidative phosphorylation. Upstream regulatory inputs include TP53 and growth factor signaling cascades, positioning MYG1 as a node connecting cellular stress responses and metabolic control. Downstream, MYG1 activity suppresses the intrinsic apoptosis pathway by preventing cytochrome c release, thereby limiting caspase-9 and caspase-3 activation. Key pathway components including BAX, BCL2, and APAF1 coordinate the mitochondrial apoptotic checkpoint, and MYG1 disruption shifts the balance toward pro-apoptotic signaling, elevating reactive oxygen species and triggering caspase-dependent cell death.
In the HeLa context, MYG1 knockout acquires particular significance due to the interplay between HPV-18-driven oncogenic stress and mitochondrial homeostasis. HPV-18 E6-mediated degradation of TP53 partially relieves apoptotic pressure, yet mitochondrial dysfunction induced by MYG1 loss can override this anti-apoptotic milieu, providing a powerful system to study synthetic lethal interactions and mitochondrial priming in cervical cancer and broader solid tumor paradigms. The model thus enables dissection of how mitochondrial gatekeeper proteins integrate with viral oncoproteins to influence cell fate decisions, drug sensitivity, and metabolic reprogramming.
Researchers can employ the MYG1 Knockout HeLa Polyclonal Cells for diverse experimental applications, including western blotting for cleaved caspase-3, PARP, and cytochrome c release; RT-qPCR to confirm MYG1 transcript depletion; MTT assays to assess proliferation changes; JC-1 staining for mitochondrial membrane potential; Annexin V/PI flow cytometry for apoptosis quantification; and Seahorse metabolic analysis to profile oxidative phosphorylation and glycolysis. These assays support investigations into mitochondrial dysfunction in cancer, apoptosis regulatory networks, and cell cycle alterations. For additional technical specifications or custom requests, please contact Ascent Research.
